Bora (6472) reported revenue of NT$1.99 billion for Oct 2026, +15.9% year on year and -14.4% from the previous month. Revenue for Jan–Oct 2026 was NT$18.29 billion (+10.1% year on year).
Year-on-year revenue growth: 6 months in a row. →
In Oct 2026, it ranked No. 3 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$1.99 billion | +15.9% | -14.4% |
| Sep 2026 | NT$2.33 billion | +35.1% | +6.4% |
| Aug 2026 | NT$2.18 billion | +59.2% | +14.9% |
| Jul 2026 | NT$1.9 billion | +5.8% | -17.2% |
| Jun 2026 | NT$2.3 billion | +39.2% | +8.7% |
| May 2026 | NT$2.11 billion | +40.2% | +42.5% |
| Apr 2026 | NT$1.48 billion | -27.5% | -2.9% |
| Mar 2026 | NT$1.53 billion | +6.3% | +15.2% |
| Feb 2026 | NT$1.33 billion | -23.2% | +16.1% |
| Jan 2026 | NT$1.14 billion | -30.2% | -31.1% |
| Dec 2025 | NT$1.66 billion | -16.6% | +10.4% |
| Nov 2025 | NT$1.5 billion | -10.8% | -12.6% |
| Oct 2025 | NT$1.72 billion | -17.8% | -0.2% |
| Sep 2025 | NT$1.72 billion | -15.0% | +25.4% |
| Aug 2025 | NT$1.37 billion | -26.6% | -23.7% |
| Jul 2025 | NT$1.8 billion | +4.5% | +8.9% |
| Jun 2025 | NT$1.65 billion | -2.7% | +9.4% |
| May 2025 | NT$1.51 billion | -10.7% | -26.3% |
| Apr 2025 | NT$2.05 billion | +24.6% | +42.3% |
| Mar 2025 | NT$1.44 billion | +91.0% | -16.8% |
| Feb 2025 | NT$1.73 billion | +96.3% | +5.5% |
| Jan 2025 | NT$1.64 billion | +33.6% | -17.6% |
| Dec 2024 | NT$1.99 billion | +107.9% | +18.0% |
| Nov 2024 | NT$1.68 billion | +49.4% | -19.4% |
| Oct 2024 | NT$2.09 billion | +85.9% | +3.2% |
Jan–Oct 2026 cumulative: NT$18.29 billion (+10.1% YoY)
Other Biotech & Medical companies
Compare with peers: Bora vs PEC / Bora vs Lotus Pharm / Bora vs Great Tree Pharmacy
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
Company remark (original Chinese)
停業單位營收累計為5,152千元
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16